Pharmacodynamics, safety, tolerability, and pharmacokinetics of the 0.8-mg dose of cerivastatin in patients with primary hypercholesterolemia
- 1 May 1999
- journal article
- clinical trial
- Published by Elsevier in The American Journal of Cardiology
- Vol. 83 (10) , 1433-1436
- https://doi.org/10.1016/s0002-9149(99)00120-4
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Management of Dyslipidemia in Adults With DiabetesDiabetes Care, 1998
- 109 Lack of pharmacokinetic interaction between cerivastatin, a new HMG-CoA reductase inhibitor, and digoxinAtherosclerosis, 1997
- 103 Phase I study to investigate the effects of cimetidine on the pharmacokinetics of cerivastatin—a new HMG-CoA reductase inhibitorAtherosclerosis, 1997
- No Pharmacokinetic or Pharmacodynamic Interaction Between Rivastatin and WarfarinThe Journal of Clinical Pharmacology, 1995
- LC separation and induced fluorometric detection of rivastatin in blood plasmaJournal of Pharmaceutical and Biomedical Analysis, 1993
- The Centers for Disease Control-National Heart, Lung and Blood Institute Lipid Standardization Program: An Approach to Accurate and Precise Lipid MeasurementsClinics In Laboratory Medicine, 1989